-
EXPRESSION OF CONCERN: A Newly Identified 45‐kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance
-
Correction to “Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma”
-
Histone Variant H2A.Z2 Hyper‐Transcription Induced by E2F1 Accelerates Lung Adenocarcinoma Progression via the JAK–STAT Signaling Pathway
-
Suppressing M2 Macrophage Polarization by Glycine Combined with β-Elemene via the IL-6/JAK2/STAT3 Signaling Pathway to Inhibit Triple-Negative Breast Cancer Progression
-
Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma
-
Emerging Agents for Boron Neutron Capture Therapy: Biomolecular Carriers Paving the Way for Precision Radiotherapy
-
Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
-
Combining radiotherapy with CAR‐T cell therapy for solid tumors: Challenges, mechanisms, and future directions
-
In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses
-
Impact of Targeted Immune Checkpoint Inhibitor Adjuvant Therapy on Recurrence-Free Survival and Functional Recovery in Stage III Tongue Cancer Patients: A Retrospective Cohort Study
-
EGFR Mutations and Recurrence Outcomes in Resected Non‐Small Cell Lung Cancer: An Updated 2015–2025 Systematic Review and Meta‐Analysis
-
Advances in Phase III Clinical Trials and Future Challenges of Targeted Therapy in Advanced Ovarian Cancer
-
Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer
-
Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study
-
Clinical Factors Associated With Non‐Completion of Durvalumab Maintenance Therapy After Chemoradiotherapy in Patients With Locally Advanced Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study
-
Targeting Temozolomide‐Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor
-
Use of histone deacetylase inhibitors (HDACis) in pancreatic ductal adenocarcinoma (PDAC): A narrative review
-
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
-
Identification of Novel Small‐Molecule Inhibitors Targeting KDM5B and Evaluation of Their Antitumour Effects
-
Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies
-
Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer
-
RETRACTION: Delanzomib, a Novel Proteasome Inhibitor, Sensitizes Breast Cancer Cells to Doxorubicin‐Induced Apoptosis
-
The Application of eHealth in Symptom Management of Patients With Breast Cancer During Endocrine Therapy: Scoping Literature Review
-
Prognostic and Predict Value of Peripheral Blood Circulating Tumor Cells Programmed Death‐Ligand 1 Expression and F‐18‐Fluorodeoxyglucose Metabolic Parameters in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
